Related Experiment Video

Updated: Apr 5, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

Candidate biomarkers in heart failure with reduced and preserved ejection fraction

Christoph Sinning1, Elvin Zengin, Tanja Zeller

  • 1a Department of General and Interventional Cardiology , University Heart Center Hamburg , Germany and.

Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|August 25, 2015
PubMed

Insights

Candidate biomarkers like GDF-15, MR-proADM, and troponin may help characterize heart failure subtypes. However, more outcome studies are needed to confirm their clinical utility in heart failure (HF) diagnosis.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Clinical Diagnostics

Background:

  • Heart failure (HF) is clinically categorized into HF with reduced ejection fraction and HF with preserved ejection fraction.
  • Accurate patient characterization is crucial for effective management and treatment strategies.

Purpose of the Study:

  • To evaluate the utility of candidate biomarkers in differentiating between HF subtypes.
  • To identify biomarkers that can provide additional characterization beyond ejection fraction.

Main Methods:

  • A comprehensive literature search was performed in MEDLINE and Cochrane Central Register of Controlled Trials.
  • The search covered studies from inception up to November 2014, including 47 diseased and general population cohorts.

Main Results:

  • Candidate biomarkers, specifically Growth Differentiation Factor 15 (GDF-15), pro-adrenomedullin (MR-proADM), and high-sensitivity troponin, show potential for characterizing HF subtypes.
  • The included cohorts provided preliminary evidence for the additional value of these biomarkers.

Conclusions:

  • Candidate biomarkers, including GDF-15, MR-proADM, and high-sensitivity troponin, show promise for enhancing HF patient characterization.
  • Further large-scale outcome studies are essential to validate these findings and establish clinical guidelines.
Abstract

Keywords:
Growth-differentiation factor 15heart failure with reduced and preserved ejection fractionhighly sensitive determined troponinsoluble source of tumorigenicity 2

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
770
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
603
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
546